Live Feeds
● LIVE Updated 29d ago · 20 sources tracked

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium Therapeutics reported positive topline results from the Phase 3 Emerge study for its DT120 orally disintegrating tablet. A single supervised dose of the LSD-based therapy significantly reduced symptoms in adults with major depressive disorder compared to a placebo. The drug demonstrated 12-week durability and met all primary and key secondary endpoints.

RSS Source map (24)

What changed

Definium Therapeutics announced positive Phase 3 trial results for its LSD-based depression treatment DT120.

Live updates

  1. Definium's LSD-Based Pill Shows Positive Phase 3 Results for Depression

    Definium Therapeutics reported positive topline results from the Phase 3 Emerge study for its DT120 orally disintegrating tablet. A single supervised dose of the LSD-based therapy significantly reduced symptoms in adults with major depressive disorder compared to a placebo. The drug demonstrated 12-week durability and met all primary and key secondary endpoints.

    What's confirmed:

    • Definium Therapeutics' DT120 orally disintegrating tablet produced positive topline results in the Phase 3 Emerge study for major depressive disorder.
    • The DT120 trial involved 149 patients and met all primary and key secondary endpoints.
    • A single supervised dose of DT120 significantly reduced symptoms of major depression compared to a placebo.
    • The treatment showed efficacy with a 12-week durability.
    • Definium Therapeutics shares rose 50% to a more than four-year high following the announcement.
    • The company is awaiting data from a second pivotal trial.

    Still unconfirmed:

    • The CEO described the trial data as the "best data ever seen".
    • Stifel stated results exceeded expectations and Jefferies called the efficacy data "profound".
    • DT120 is the first psychedelic to achieve positive Phase 3 data.
    confidence 100%